Recent news on Toremifene

Toremifene Citrate Increases Bone Mineral Density in Prostate ...  -  25 May 2007
DG NewsToremifene citrate significantly increased BMD of the lumbar spine, total hip and femoral neck in an interim analysis of 12-month BMD changes for 197

GTx Announces Presentation of Ostarine™ and ACAPODENE® Data at ...  -  25 May 2007
Business Wire (press release),...the ongoing Phase III clinical trial evaluating ACAPODENE® (toremifene citrate) 80 mg for the treatment of multiple side effects of androgen deprivation

GTx Announces Webcast of Corporate Presentation at Citigroup ...  -  May 17, 2007
PharmaLive.com (press release),GTx is developing ACAPODENE(R) (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first,

DRUGS IN DEVELOPMENT  -  Apr 17, 2007
PharmaLive.com (press release),Toremifene is predicted to reach the market in late 2008/early 2009 for the prevention of prostate cancer in men with high-grade prostatic intraepithelial

Fareston® May Decrease Side Effects of Androgen Deprivation Therapy  -  Apr 2, 2007
Cancer Consultants (press release),Researchers from the Massachusetts General Hospital have reported that the administration of Fareston (toremifene citrate), an anti-estrogen,

GTx, Inc. Announces First Quarter 2007 Financial Results ...  -  Apr 20, 2007
PharmaLive.com (press release),GTx is developing ACAPODENE(R) (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first,

ASCO PROSTATE: Toremifene May Ease Androgen Deprivation Complications  -  Feb 23, 2007
MedPage Today,23 -- The selective estrogen receptor modulator toremifene (Acapodene) improved lipid profiles and increased bone mineral density in androgen deprivation

Toremifene may curb impact of androgen deprivation therapy in ...  -  Feb 23, 2007
Therapeutics Daily (subscription) (press release),NEW YORK (Reuters Health) - The selective estrogen receptor modulator toremifene significantly increases bone mineral density and improves lipid profiles in

GTX releases positive data for prostate cancer drug  -  Feb 23, 2007
MarketWatchThe Phase III data unveiled Friday showed that Acapodene, also known as toremifene, was effective in both increasing bone density and improving levels of

GTx's ACAPODENE Interim Bone Mineral Density and Lipid Data ...  -  Feb 23, 2007
PharmaLive.com (press release),GTx is developing ACAPODENE(R) (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first,

GTx's Phase III Clinical Development of ACAPODENE on Course ...  -  Feb 2, 2007
Genetic Engineering News (press release),There are more than 350000 patient years of experience with toremifene 60 mg, which has already been approved for the treatment of advanced breast cancer.

GTx Announces Presentation of Acapodene Data At ASCO Prostate ...  -  Feb 21, 2007
PharmaLive.com (press release),Both analyses were conducted in the first 197 men to complete one year of treatment in the Phase III clinical trial evaluating ACAPODENE(R) (toremifene

GTx Reports Fourth Quarter and Year End 2006 Results  -  Feb 20, 2007
PharmaLive.com (press release),GTx is developing ACAPODENE(R) (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first,

MacroArray Technologies Announces the Identification of a Urine ...  -  Feb 14, 2007
Business Wire (press release),GTx is conducting a pivotal Phase III clinical trial of ACAPODENE® (toremifene citrate) 20 mg for the prevention of prostate cancer in men with high grade

Biotech Day in Review: Big Pharma Merger in Japan  -  Feb 4, 2007
Seeking Alpha,A form of the breast cancer drug toremifene, Acapodene is being tested as a treatment for the side effects of androgen deprivation therapy for prostate

Faslodex® Benefits Subset of Women Resistant to Aromatase Inhibitors  -  Feb 1, 2007
Cancer Consultants (press release),...after treatment with an aromatase inhibitor and many of the women had also received prior treatment with tamoxifen or toremifene (Fareston®).

GTx Announces Webcast of Corporate Presentation at the JP Morgan ...  -  18 Jan 2007
PharmaLive.com (press release),GTx is developing ACAPODENE(R) (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first,

GTx Announces Registered Direct Common Stock Offering of $60.8 Million  -  Dec 14, 2006
PharmaLive.com (press release),GTx is developing ACAPODENE(R) (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first,

GTx, Inc. Reports Third Quarter 2006 Financial Results  Nov 2, 2006
Revenues in all periods included net sales of FARESTON(R) (toremifene citrate 60 mg), marketed for the treatment of metastatic breast cancer, and collaboration ... -Genetic Engineering News (press release), GTx Announces Webcast of Corporate Presentation at the Cowen and ...  Nov 1, 2006
GTx is developing ACAPODENE(R) (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, a ... -PharmaLive.com (press release), GTx Announces Webcast of Corporate Presentation at the UBS Global ...  Sep 21, 2006
GTx is developing ACAPODENE(R) (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, a ... -PR Newswire

Ipsen and GTx Enter into Partnership Agreement for The European ...  Sep 7, 2006
...they have entered into a definitive agreement under which Ipsen will have an exclusive license to develop and market GTx's Acapodene(R) (toremifene citrate) in ... -PipelineReview.com

Ipsen Licenses GTx' SERM Acapodene in EU  Sep 12, 2006
...agreement under which the former licenses European development rights to the latter's selective estrogen receptor modulator Acapodene (toremifene citrate), in ... -Therapeutics Daily (subscription)

GTx's Phase III Clinical Development of ACAPODENE on Course ...  Sep 5, 2006
Monitoring Board (DSMB) recommended that GTx continue clinical development as planned with its two pivotal Phase III trials of ACAPODENE® (toremifene citrate ... -Yahoo! News

France's Ipsen expands in cancer with GTx deal  Sep 6, 2006
2005. GTx is developing Acapodene or toremifene citrate in two final Phase III clinical trials for two separate indications in men. ... -Reuters

France's Ipsen expands in cancer with GTx deal  Sep 6, 2006
GTx is developing Acapodene or toremifene citrate, which is already sold as a breast cancer treatment and is branded in Europe as Fareston, in two final Phase ... -Reuters

Ipsen pays 23 mln eur for rights to develop GTX's Acapodene in ...  Sep 7, 2006
...group Ipsen said it has agreed to pay GTx Inc 23 mln eur or about 30 mln usd for a licence to develop and market GTx's Acapodene (toremifene citrate) in Europe ... -Forbes

GTx, Ipsen Sign Partnership Deal For Acapodene's European Rights ...  Sep 7, 2006
Under the agreement, Ipsen would have an exclusive license to develop and market GTx's Acapodene or toremifene citrate in all indications except breast cancer ... -Trading Markets

- Ostarine achieved the primary endpoint of increasing lean body ...  -  Dec 8, 2006
PR Newswire (press release),GTx is developing ACAPODENE(R) (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first,

Researchers Probe Consequences of Androgen Deprivation for ...  -  Nov 14, 2006
Journal of American Medical Association (subscription),And preliminary evidence suggests that the selective estrogen receptor modulators raloxifene and toremifene can prevent bone loss induced by androgen

GTx, Inc. Reports Second Quarter 2006 Financial Results  Jul 27, 2006
Revenues in all periods included net sales of FARESTON(R) (toremifene citrate 60 mg), marketed for the treatment of metastatic breast cancer, and collaboration ... -MSN Money

GTx Announces Webcast of Corporate Presentation at the Bank of ...  Aug 3, 2006
GTx is developing ACAPODENE® (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, a ... -Yahoo! News

GTx, Inc. Completes Enrollment of Phase II Ostarine Trial  Jul 21, 2006
GTx is developing ACAPODENE(R) (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, a ... -Drug Newswire

Side effects drug lowers cholesterol, bone loss  Jun 24, 2006
...a study led by Dr. Matthew Smith, associate professor of medicine at Harvard Medical School, the researchers found that the drug toremifene citrate (ACAPODENE ... -Cancerfacts.com



Cordova High-Rise Sells for $19.3 Million  May 15, 2006
GTx is developing ACAPODENE (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, a pivotal ... - Memphis Daily News

GTx, Inc. Attains Enrollment Goal for Phase III PIN Clinical Trial  May 3, 2006
...pathologist, David Bostwick, MD Patients in the clinical trial were randomized to receive daily for three years either ACAPODENE (toremifene citrate) in a 20 ... - PharmaLive.com

GTX, Inc. Reports First Quarter 2006 Financial Results  Apr 27, 2006
Revenues included net sales of FARESTON(R) (toremifene citrate 60 mg), marketed for the treatment of metastatic breast cancer in postmenopausal women, and ... - PR Newswire

GTx, Inc. Announces Initiation of Phase IIIb Extension Trial of ...  Apr 21, 2006
...it is initiating a separate Phase IIIb clinical trial as an extension of the pivotal Phase III ADT clinical trial of ACAPODENE® (toremifene citrate) in an ... - Yahoo! News

Orion Oyj: Orion group interim report 1-3/2006  May 8, 2006
...is progressing with its phase 3 clinical trials with toremifene (GTx’s trade name AcapodeneTM), an antiestrogen developed by Orion Pharma, for the prevention ... - Kauppalehti

GTx Q1 Loss Per Share Narrows, To File NDA During 2008 - Quick ...  Apr 27, 2006
...announce within one week that it has attained enrollment goal of 1,260 men in its pivotal Phase III clinical trial evaluating ACAPODENE toremifene citrate in a ... - Trading Markets





MacroArray Technologies to Present Data on a Urine-Based ...  Mar 31, 2006
GTx is conducting a pivotal Phase III clinical trial of ACAPODENE® (toremifene citrate) in a 20 mg dose for the prevention of prostate cancer in men with high ... - Yahoo! News



Orion Oyj: Orion group 2005 financial statements  Feb 9, 2006
The breast cancer drug Fareston® (toremifene), which is an antiestrogen, received marketing authorisation in the United States in 1997. ... - Kauppalehti,

Ocular Side Effects Common with Adjuvant Chemo for Early Breast ...  Feb 15, 2006
1999. The women were randomized to receive endocrine therapy with a SERM (tamoxifen or toremifene) alone or with chemotherapy. A ... - Cancerpage.com,

GTx and Gen-Probe to Study the Ability of Research-Stage ...  Jan 31, 2006
...of the agreement, GTx will provide Gen-Probe with urine samples from patients enrolled in GTx's clinical trials testing ACAPODENE(R) (toremifene citrate 20mg ... - PR Newswire,

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional